Stockscreener 앱 받기
5.40
1.69%
0.09
Alterity Therapeutics Ltd Adr 주식(ATHE)의 최신 뉴스
ATHE: A Tale of Ups & Downs – 63.16% gain in 6 Months, 42.35% in 30 Days - investchronicle.com
SMCI’s Market Flip-Flop: Exploring the Volatility of 2025 Performance - investchronicle.com
Alterity CEO to provide corporate update on ATH434 development By Investing.com - Investing.com India
Alterity Therapeutics highlighted at MSA Congress - Investing.com
Alterity Therapeutics highlighted at MSA Congress By Investing.com - Investing.com India
Alterity Therapeutics reports Phase 2 data at MSA Congress - Investing.com
Alterity Therapeutics reports Phase 2 data at MSA Congress By Investing.com - Investing.com South Africa
Alterity shares new phase 2 data on MSA treatment - Investing.com
Alterity Therapeutics announces regulatory notice - Investing.com
Alterity Therapeutics completes placement - Investing.com
Alterity Therapeutics announces regulatory notice By Investing.com - Investing.com UK
Alterity Therapeutics completes placement By Investing.com - Investing.com UK
ATHEAlterity Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan
Alterity Concludes Open-Label Trial Patient Visits - Investing.com
Alterity Therapeutics announces compliance notice - Investing.com
Alterity Therapeutics Issues Over 1 Billion New Shares - TipRanks
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.
Alterity Therapeutics raises A$40M in placement - TipRanks
Alterity secures funding to advance MSA drug development - Investing.com India
Alterity Therapeutics announces trading halt - Investing.com
Alterity Therapeutics Initiates Trading Halt for Capital Raising Announcement - TipRanks
Alterity Therapeutics reports compliance with Takeovers Panel By Investing.com - Investing.com South Africa
Alterity Therapeutics reports compliance with Takeovers Panel - Investing.com
Alterity Therapeutics announces securities notice - Investing.com
Alterity Therapeutics Completes Significant Share Issuance - TipRanks
Alterity Therapeutics announces ATH434 Phase 2 trial results - MSN
Alterity Therapeutics Initiates Trading Halt Pending Phase II Trial Results - TipRanks
Alterity Therapeutics reports quarterly activities - Investing.com
Alterity Therapeutics Expands ASX Quoted Securities - TipRanks
Alterity Therapeutics Reports Key Advances and Anticipates Milestones in 2025 - TipRanks
Alterity Therapeutics Highlights Key Milestones in Neurodegenerative Disease Pipeline - TipRanks
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Most active stocks: US stocks with the highest trading volume today - Yahoo
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns - Stockhead
symbol__ Stock Quote Price and Forecast - CNN
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money ... - Stockhead
Biotech Stocks: Longevity Company Stocks - Investing.com
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
Biggest Stock LosersToday’s Biggest Percentage Decliners - MarketBeat
Alterity Therapeutics LtdADR Shares Close the Week 40.3% HigherWeekly Wrap - Nasdaq
Most Volatile Stocks, What Investors Need to Know - MarketBeat
ASE Technology Holding Co., Ltd. American Depositary Shares (each representing (NY: ASX - Financial Content
A Full List of Australia ADRs - Investing.com Australia
How Investors Can Identify and Successfully Trade Gap-Down Stocks - MarketBeat
What Investors Need to Know to Beat the Market - MarketBeat
Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time - MarketBeat
0.24%
3.39%
자본화:
|
볼륨(24시간):